ライフサイエンスコーパス: spondylitis

1 spondyloarthritis (also known as ankylosing spondylitis).

2 n which uveitis coincides with arthritis and spondylitis.

3 tory bowel disease, psoriasis and ankylosing spondylitis.

4 or autoimmune diseases, including ankylosing spondylitis.

5 and nonpharmacologic therapies in ankylosing spondylitis.

6 f benefit to select patients with ankylosing spondylitis.

7 arthritis, reactive arthritis, or ankylosing spondylitis.

8 nderstanding the genetic basis of ankylosing spondylitis.

9 atosus, rheumatoid arthritis, and ankylosing spondylitis.

10 fective for signs and symptoms of ankylosing spondylitis.

11 l deformities similar to those in ankylosing spondylitis.

12 be effective in the treatment of ankylosing spondylitis.

13 of the genetic susceptibility to ankylosing spondylitis.

14 le in delaying the progression of ankylosing spondylitis.

15 attenuate spinal inflammation in ankylosing spondylitis.

16 can prevent structural damage in ankylosing spondylitis.

17 effective in phase III trials in ankylosing spondylitis.

18 be asymptomatic, as in classical ankylosing spondylitis.

19 fusion protein, in patients with ankylosing spondylitis.

20 ined improvement in patients with ankylosing spondylitis.

21 a, seem not to be associated with ankylosing spondylitis.

22 a potential therapeutic target in ankylosing spondylitis.

23 siblings of female patients with ankylosing spondylitis.

24 JAK1 inhibitor, in patients with ankylosing spondylitis.

25 an TRBV9(+) T cell elimination in ankylosing spondylitis.

26 oriasis, psoriatic arthritis, and ankylosing spondylitis.

27 to be effective in patients with ankylosing spondylitis.

28 ory bowel diseases, psoriasis, or ankylosing spondylitis.

29 re associated with development of ankylosing spondylitis.

30 opathies, psoriatic arthritis and ankylosing spondylitis.

31 cukinumab in patients with active ankylosing spondylitis.

32 h the overall lack of efficacy in ankylosing spondylitis.

33 he modified New York criteria for ankylosing spondylitis.

34 isease, rheumatoid arthritis, and ankylosing spondylitis.

35 association of both molecules in ankylosing spondylitis.

36 l spondyloarthropathies, which is ankylosing spondylitis.

37 soriasis, psoriatic arthritis, or ankylosing spondylitis.

38 es differentially associated with ankylosing spondylitis.

39 ed for the development of EO, arthritis, and spondylitis.

40 y diseases, notably psoriasis and ankylosing spondylitis.

41 (1346+/-1011 pg per milliliter), ankylosing spondylitis (1368+/-1162 pg per milliliter), or liver fi

42 ents achieving the Assessments in Ankylosing Spondylitis 20% response (ASAS20) at weeks 12 and 24.

43 ignificantly after MR imaging for ankylosing spondylitis (29% vs 80%, P < .001), undifferentiated spo

44 arthritis (5 phase 3 trials), and ankylosing spondylitis (4 phase 3 trials).

45 mechanical back pain (4% vs 49%, P < .001), spondylitis (7% vs 76%, P < .001) and sacroiliitis (9% v

46 n had an even higher incidence of ankylosing spondylitis (7.2 [1.5-34], p=0.013) than did children of

47 , 48.8 [12.1] years), and 977 had ankylosing spondylitis (7.3%; 658 men [67.3%]; mean [SD] age, 42.3

48 ip between the gut microbiome and ankylosing spondylitis, a quantitative metagenomics study based on

49 Long-Term Efficacy and Safety in Ankylosing Spondylitis, a randomized controlled study, were randoml

50 and valve disease associated with ankylosing spondylitis (AKS).

51 tive arthritis, sacroiliitis, and ankylosing spondylitis also appear to be increased in these people,

52 28 and 575/725 is associated with ankylosing spondylitis among HLA-B27-positive individuals.

53 nostic approach in the case of sacroiliitis, spondylitis and arthritis.

54 PsA, a new composite measure for ankylosing spondylitis and axial SpA, the ASDAS, new measures for t

55 pathic changes closely resembling ankylosing spondylitis and DISH.

56 ious physical therapy programs in ankylosing spondylitis and identify their benefits and potential in

57 ed novel roles for these drugs in ankylosing spondylitis and in cancer prevention, accumulating evide

58 phase III trials of patients with ankylosing spondylitis and in trials conducted a decade ago in pati

59 However, ankylosing spondylitis and inflammatory bowel disease were not conc

60 es indicate that the morbidity of ankylosing spondylitis and PsA are considerably higher than previou

61 Three risk loci shared with ankylosing spondylitis and psoriasis (the MHC class I region, ERAP1

62 atoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis, confirms the importance of TN

63 atoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis.

64 ated disorders, most notably with ankylosing spondylitis and psoriasis.

65 or necrosis factor antagonists in ankylosing spondylitis and psoriatic arthritis has generated consid

66 ctor inhibitors for patients with ankylosing spondylitis and psoriatic arthritis has had a tremendous

67 azine is moderately effective for ankylosing spondylitis and psoriatic arthritis, although the large

68 reatest experience has accrued in ankylosing spondylitis and psoriatic arthritis.

69 nal status and quality of life in ankylosing spondylitis and psoriatic arthritis.

70 mor necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.

71 ive and safe for the treatment of ankylosing spondylitis and psoriatic arthritis.

72 ammatory diseases including psoriasis, axial spondylitis and psoriatic arthritis.

73 healthy donors and patients with ankylosing spondylitis and psoriatic arthritis.

74 Ankylosing spondylitis and related spondylarthritides are associate

75 -B27 in genetic susceptibility to ankylosing spondylitis and related spondyloarthropathies, although

76 son with originator infliximab in ankylosing spondylitis and rheumatoid arthritis; however, concerns

77 major histocompatibility complex (ankylosing spondylitis and sacroiliitis, P = 1.4E-15; OR, 2.5; 95%

78 EIMs (eg, ankylosing spondylitis [ankylosing spondylitis and sacroiliitis], primary sclerosing cholan

79 ic arthritis, reactive arthritis, ankylosing spondylitis), and osteoarthritis have characteristic app

80 ed diseases, including psoriasis, ankylosing spondylitis, and Behcet disease.

81 dose (Ikbkb(GoF/GoF)) results in dactylitis, spondylitis, and characteristic nail changes, which are

82 ith systemic lupus erythematosus, ankylosing spondylitis, and hepatic fibrosis.

83 atoid arthritis, IgA nephropathy, ankylosing spondylitis, and inflammatory bowel disease (IBD).

84 ammation in rheumatoid arthritis, ankylosing spondylitis, and juvenile chronic arthritis.

85 ve structure-modifying effects in ankylosing spondylitis, and may thereby alter the disease course.

86 ases such as behcet's disease and ankylosing spondylitis, and ocular involvement of infectious diseas

87 ic arthritis, reactive arthritis, ankylosing spondylitis, and osteoarthritis.

88 However, anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis usually

89 one in detail, a risk allele for ankylosing spondylitis, and provide direct evidence of a non-coding

90 (psoriatic arthritis, psoriasis, ankylosing spondylitis, and rheumatoid arthritis), we tested whethe

91 lity, early onset osteoarthritis, ankylosing spondylitis, and seronegative erosive rheumatoid arthrit

92 in RA but also in Crohn disease, ankylosing spondylitis, and several other chronic inflammatory diso

93 tica (PMR), giant cell arteritis, ankylosing spondylitis, and Sjogren's syndrome, and to provide an o

94 ondyloarthritides, including PsA, ankylosing spondylitis, and the broader categories of SpA may be pr

95 -modifying role of these drugs in ankylosing spondylitis, and their use in the understudied pediatric

96 olitis, peripheral arthritis, and occasional spondylitis, and those with lower transgene copy numbers

97 ents with gout, two patients with ankylosing spondylitis, and two patients with psoriatic arthritis,

98 presence or absence of EIMs (eg, ankylosing spondylitis [ankylosing spondylitis and sacroiliitis], p

99 Patients with juvenile-onset ankylosing spondylitis appear to have poorer functional outcomes.

100 id arthritis, where patients with ankylosing spondylitis are offered therapy early in the disease cou

101 The spondylarthritides (such as ankylosing spondylitis) are multisystem inflammatory diseases that

102 This group includes 6 entities: ankylosing spondylitis, arthritis associated with inflammatory bowe

103 sample of two new loci related to ankylosing spondylitis, ARTS1 and IL23R, and confirmation of the pr

104 pus erythematosus (SLE) (n = 10), ankylosing spondylitis (AS) (n = 10), primary Sjogren's syndrome (n

105 Ankylosing spondylitis (AS) affects 0.25-1.0% of the population, an

106 ilarities and differences between ankylosing spondylitis (AS) and axial psoriatic arthritis (PsA).

107 their application in a number of ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA) Reg

108 DCT) findings of 41 patients with ankylosing spondylitis (AS) and compared them with pulmonary functi

109 ciated with predisposition toward ankylosing spondylitis (AS) and other spondyloarthropathies.

110 e inflammatory arthritis disorder ankylosing spondylitis (AS) and with other related spondylarthropat

111 Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic inflammatory diseases that

112 pproximately 40% of patients with ankylosing spondylitis (AS) but also affects patients with no evide

113 ), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) from 526 subjects overall.

114 e develops a phenotype similar to ankylosing spondylitis (AS) in humans.

115 MRI-evident sacroiliitis develop ankylosing spondylitis (AS) in the long term and whether there are

116 Ankylosing spondylitis (AS) is a chronic inflammatory arthritis aff

117 Ankylosing spondylitis (AS) is a chronic inflammatory arthritis tha

118 Ankylosing spondylitis (AS) is a chronic inflammatory disorder of u

119 Ankylosing spondylitis (AS) is a common and highly familial rheumat

120 Ankylosing spondylitis (AS) is a common, highly heritable, inflamma

121 We investigated the proposal that ankylosing spondylitis (AS) is associated with unusual ERAP1 genoty

122 Ankylosing spondylitis (AS) is the prototypic form of SpA in which

123 of the gene-regulatory network in ankylosing spondylitis (AS) is vital for elucidating the mechanisms

124 Ankylosing spondylitis (AS) may present with extra-articular involv

125 The clinical response in ankylosing spondylitis (AS) patients treated with biologic agents c

126 nal inflammation in patients with ankylosing spondylitis (AS) relies primarily on magnetic resonance

127 e HLA-B27-transgenic rat model of ankylosing spondylitis (AS) suggested that macrophages develop an i

128 ong association between ERAP1 and ankylosing spondylitis (AS) was recently identified by the Wellcome

129 he spine and pelvis (for example, ankylosing spondylitis (AS)) and the eye (that is, acute anterior u

130 associated with susceptibility to ankylosing spondylitis (AS), and those reported not to be associate

131 s from 1,000 independent cases of ankylosing spondylitis (AS), autoimmune thyroid disease (AITD), mul

132 e B27 is strongly associated with ankylosing spondylitis (AS), but the pathogenic role of HLA-B27 is

133 heritability of susceptibility to ankylosing spondylitis (AS), it is only recently that the involveme

134 heral articular manifestations of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and reactiv

135 of rheumatologists' diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), or reactive

136 ondyloarthropathies (SpA) include ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive ar

137 reticulum aminopeptidase 1) with ankylosing spondylitis (AS), which is restricted to HLA-B27 positiv

138 ssary to establish a diagnosis of ankylosing spondylitis (AS).

139 age in patients with longstanding ankylosing spondylitis (AS).

140 iation with the rheumatic disease ankylosing spondylitis (AS).

141 e (HRQOL) in patients with active ankylosing spondylitis (AS).

142 role in the spondylarthropathy of ankylosing spondylitis (AS).

143 ine (SP), in patients with active ankylosing spondylitis (AS).

144 manifests the clinical feature of ankylosing spondylitis (AS).

145 ith rheumatoid arthritis (RA) and ankylosing spondylitis (AS).

146 of osteoporosis in patients with ankylosing spondylitis (AS).

147 les due to their association with Ankylosing Spondylitis (AS).

148 revolutionized the management of ankylosing spondylitis (AS); however, the lack of notable clinical

149 the chronic inflammatory disease Ankylosing Spondylitis (AS); however, the mechanisms underlying thi

150 vented the subsequent onset of arthritis and spondylitis, as did transgene-induced azospermia.

151 ASsessment of Ankylosing Spondylitis (ASAS) International Working Group criteria

152 e conformations in differentially ankylosing spondylitis-associated subtypes) must not be excluded fr

153 utoimmune damage in patients with ankylosing spondylitis-associated subtypes.

154 ions in the signs and symptoms of ankylosing spondylitis at week 16.

155 ive study involving patients with ankylosing spondylitis, behcet's disease, presumed sarcoidosis, pre

156 ving the pain of axial disease in ankylosing spondylitis but these findings contradict two previous s

157 ptibility and disease activity of ankylosing spondylitis, but the effect of HLA-B27 on the activity o

158 ociation study in 2,053 unrelated ankylosing spondylitis cases among people of European descent and 5

159 n in an independent cohort of 898 ankylosing spondylitis cases and 1,518 controls.

160 the course of the disease, Stoke Ankylosing spondylitis classification Spinal Score (SASSS) is recom

161 l Consortium and the Australo-Anglo-American Spondylitis Consortium (WTCCC-TASC) study.

162 stigated the genetic landscape of ankylosing spondylitis, Crohn's disease, psoriasis, primary scleros

163 ultiple sclerosis (D12S1052), and ankylosing spondylitis (D16S516).

164 and 45 controls: alopecia areata, ankylosing spondylitis, dermatomyositis, Graves' disease, Hashimoto

165 nd MMP-3 correlated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) values, but

166 A modified Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to

167 ase activity assessed by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and functio

168 unctional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and the Ank

169 activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), pain and mo

170 ivity was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).

171 activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (P = 0.002).

172 y and functional parameters (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI], Bath Ankylo

173 02; 95% CI, 0.00-0.11), and 2 had ankylosing spondylitis (EAIR, 0.08; 95% CI, 0.01-0.28).

174 using the PsA-modified Maastricht Ankylosing Spondylitis Enthesitis Score [MASES] index).

175 atoid arthritis, Crohn's disease, ankylosing spondylitis, familial Mediterranean fever, and Castleman

176 is; 16 had scleroderma; eight had ankylosing spondylitis; five had juvenile RA; three had discoid lup

177 oriatic arthritis, and those with ankylosing spondylitis from phase III trials of golimumab.

178 Eligible patients had active ankylosing spondylitis, fulfilled modified New York criteria, were

179 nts included the BASDAI, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Ankylosing Spo

180 ores for entheseal pain, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosin

181 l impairment assessed by the Bath Ankylosing Spondylitis Functional Index (BASFI).

182 ions were assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI; score range 0-100,

183 ase Activity Index [BASDAI], Bath Ankylosing Spondylitis Functional Index [BASFI], and Bath Ankylosin

184 unctional Index [BASFI], and Bath Ankylosing Spondylitis Global Index [BASGI]).

185 ammation and structural damage in ankylosing spondylitis has been an important focus of recent studie

186 Importantly, psoriatic spondylitis has been observed in the absence of sacroili

187 Medical therapy of ankylosing spondylitis has improved dramatically with the advent of

188 is, but an infectious trigger for ankylosing spondylitis has not yet been established.

189 nts with rheumatoid arthritis and ankylosing spondylitis have been reported, and generic quality-of-l

190 soriatic arthritis and uveitis in ankylosing spondylitis, have also been observed.

191 IL-23 receptor are associated with ankyosing spondylitis, however, it remains unclear whether IL-23 a

192 shown to control the symptoms of ankylosing spondylitis in a phase 2 trial.

193 ining increased susceptibility to ankylosing spondylitis in children.

194 slows radiographic progression in ankylosing spondylitis in data from clinical trials may be because

195 g Pgis2 locus, inducing as high incidence of spondylitis in F2 hybrids as was found in the spondyliti

196 Severity of spondylitis in F2 mice positively correlated with serum

197 ns in human genome, which control ankylosing spondylitis in human patients.

198 hed clinical account of a case of ankylosing spondylitis in the United States.

199 nce, severity, and duration of arthritis and spondylitis, in the absence of colitis.

200 has relevance to diseases such as ankylosing spondylitis, in which HLA-B27 and ERAP jointly contribut

201 ic anemia, pernicious anemia, and ankylosing spondylitis), infectious (pneumonia, hepatitis, meningit

202 oL) instrument, the ASsessment in Ankylosing Spondylitis International Working Group criteria (ASAS)

203 Ankylosing spondylitis is a common form of inflammatory arthritis p

204 Ankylosing spondylitis is a genetically determined and commonly fam

205 Ankylosing spondylitis is an inflammatory autoimmune disease and ev

206 Ankylosing spondylitis is associated with increased risk for vascul

207 ciation further substantiate that ankylosing spondylitis is determined to a large extent by genes out

208 w York criteria, the diagnosis of ankylosing spondylitis is made based on the presence of advanced le

209 rly half of the susceptibility to ankylosing spondylitis is provided by major histocompatibility comp

210 f the major goals of treatment of ankylosing spondylitis is to prevent or slow the development of spi

211 The prototypical type of axSpA, ankylosing spondylitis, is thought to be caused by interaction betw

212 soriasis/psoriatic arthritis, and ankylosing spondylitis) linked to newborns with periconception medi

213 disease and evidence showed that ankylosing spondylitis may be a microbiome-driven disease.

214 nal mobility metrics and the Bath Ankylosing Spondylitis Metrology Index (BASMI).

215 this animal model of experimentally induced spondylitis might facilitate the identification of spond

216 mmune-mediated diseases including ankylosing spondylitis, multiple sclerosis, and inflammatory bowel

217 ile rheumatoid arthritis (n = 3), ankylosing spondylitis (n = 1), and psoriatic spondylarthropathy (n

218 Janus kinase (JAK) inhibitors for ankylosing spondylitis, new data on the effect of biologic DMARDs o

219 d arthritis, psoriatic arthritis, ankylosing spondylitis, non-infectious uveitis, and multiple sclero

220 led RCTs of rheumatoid arthritis, ankylosing spondylitis, optic neuritis, systemic lupus erythematosu

221 % CI, 1.03-1.72) and negative for ankylosing spondylitis (OR = 0.72; 95% CI, 0.54-0.98) and rheumatoi

222 , psoriasis, psoriatic arthritis, ankylosing spondylitis, or inflammatory bowel disease using Medicar

223 (psoriasis, psoriatic arthritis, ankylosing spondylitis, or juvenile arthritis), as an active compar

224 gnosed with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis and 219 healthy cont

225 , psoriasis, psoriatic arthritis, ankylosing spondylitis, or rheumatoid arthritis exhibited greater w

226 ions convincingly associated with ankylosing spondylitis (P < 5 x 10(-8) in the combined discovery an

227 presumed sarcoidosis compared to ankylosing spondylitis (p = 0.0001), behcet's disease (p = 0.0001),

228 sumed sarcoidosis with respect to ankylosing spondylitis (p = 0.0001), behcet's disease, (p = 0.0001)

229 wo new genes, IL23R and ARTS1, in ankylosing spondylitis pathogenesis.

230 e differentially abundant between ankylosing spondylitis patients and healthy controls.

231 A recent trial in ankylosing spondylitis patients demonstrated continuous nonsteroida

232 Specifically, the ankylosing spondylitis patients demonstrated increases in the abund

233 In ankylosing spondylitis patients, IL-6 and LRG-1 were identified as

234 sis patients and in 3 of 12 (25%) ankylosing spondylitis patients.

235 in probiotics, accumulated in the ankylosing spondylitis patients.

236 ermissive genetic locus in murine PG-induced spondylitis (PGIS).

237 in the pharmacological therapy of ankylosing spondylitis, physical therapy remains an essential part

238 gher significant association with ankylosing spondylitis, polymyositis, psoriasis, rheumatoid arthrit

239 the spinal cord in the course of ankylosing spondylitis, present in MRI include: bone marrow edema,

240 ed to inflammatory bowel disease, ankylosing spondylitis, primary sclerosing cholangitis and Takayasu

241 genesis or development process of ankylosing spondylitis, providing new leads for the development of

242 soriasis, psoriatic arthritis, or ankylosing spondylitis (psoriasis and spondyloarthropathies) combin

243 eria for SpA, without evidence of ankylosing spondylitis, psoriasis, inflammatory bowel disease, or p

244 sociated with the pathogenesis of ankylosing spondylitis, psoriatic arthritis and acute anterior uvei

245 reatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenile idiopathi

246 diseases other than RA, including ankylosing spondylitis, psoriatic arthritis, and polymyositis, in 3

247 el disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis are asso

248 el disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.

249 category of spondyloarthropathy (ankylosing spondylitis, psoriatic arthritis, reactive arthritis, un

250 tis Functional Index (BASFI), the Ankylosing Spondylitis Quality of Life (ASQoL) instrument, the ASse

251 Form 36 (SF-36) Health Survey and Ankylosing Spondylitis Quality of Life (ASQoL) Questionnaire.

252 Activity Index (BASDAI), and the Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire.

253 ips were scored by using the Bath Ankylosing Spondylitis Radiology Index (BASRI) by an experienced ra

254 graphs were scored using the Bath Ankylosing Spondylitis Radiology Index for the spine (BASRI-s), and

255 c diseases that primarily include ankylosing spondylitis, reactive arthritis, and the arthritis assoc

256 Previously, the diagnosis of ankylosing spondylitis required advanced changes on plain radiograp

257 gical conditions (i.e. psoriasis, ankylosing spondylitis, rheumatoid arthritis, fibromyalgia) than th

258 orders, including osteoarthritis, ankylosing spondylitis, rheumatoid arthritis, heterotopic ossificat

259 four genetic loci associated with ankylosing spondylitis risk and identifies a major role for the int

260 class I presentation, only affect ankylosing spondylitis risk in HLA-B27-positive individuals.

261 in, muscular back pain, radicular back pain, spondylitis, sacroiliitis, and other) and overall diagno

262 sample of members of the National Ankylosing Spondylitis Society.

263 oriasis, psoriatic arthritis, and ankylosing spondylitis, sparking efforts to develop orally bioavail

264 which were scored using the Stoke Ankylosing Spondylitis Spine Score.

265 Patients who had vertebral fracture, spondylitis-spondylodiscitis, tumours, structural anomal

266 ARDs on structural progression in ankylosing spondylitis, strategy trials on tapering or stopping TNF

267 erleukin-1 (IL-1) region genes in ankylosing spondylitis suggested the susceptibility to be conferred

268 ta-analysis of published scans of ankylosing spondylitis susceptibility has confirmed sites on chromo

269 stocompatibility complex genes in ankylosing spondylitis susceptibility, and suggests areas for futur

270 ity complex), 10q, 16q and 19q in ankylosing spondylitis susceptibility.

271 The dominant spondylitis-susceptibility allele for Pgis2 locus is der

272 litis might facilitate the identification of spondylitis-susceptibility genes in humans.

273 pondylitis in F2 hybrids as was found in the spondylitis-susceptible parent BALB/c strain.

274 arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, and multiple

275 arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, Sjogren syndr

276 thematosus, rheumatoid arthritis, ankylosing spondylitis, systemic sclerosis, Sjogren syndrome and os

277 multiple sclerosis, psoriasis and ankylosing spondylitis that inclusion of known covariates can subst

278 fective structure modification in ankylosing spondylitis, the data strongly suggest a benefit, at lea

279 As in human ankylosing spondylitis, the MHC was the major permissive genetic lo

280 evidence that HLA-B27 operates in ankylosing spondylitis through a mechanism involving aberrant proce

281 erapy should remain a mainstay of ankylosing spondylitis treatment complementing medical therapy.

282 ay result in a paradigm shift for ankylosing spondylitis treatment similar to that undergone for rheu

283 ntial change from when the entity ankylosing spondylitis was defined by the modified New York criteri

284 Autoimmune spondylitis was induced in BALB/c mice and their MHC-mat

285 Ankylosing spondylitis was more prevalent among children (odds rati

286 identify susceptibility loci for ankylosing spondylitis, we undertook a genome-wide association stud

287 % of patients were diagnosed with ankylosing spondylitis were ascertained from a database of 4400 cas

288 nd histopathologic severity of arthritis and spondylitis were evaluated.

289 major genetic loci Pgis1 and Pgis2 of murine spondylitis were homologous to chromosome regions in hum

290 atients with active, inflammatory ankylosing spondylitis were randomly assigned to receive twice-week

291 th psoriatic arthritis and 1 with ankylosing spondylitis) were isolated by positive selection and sti

292 ces spinal inflammation in active ankylosing spondylitis when compared to placebo; there was no compa

293 are few effective treatments for ankylosing spondylitis, which causes substantial morbidity.

294 omplex genes in predisposition to ankylosing spondylitis, which will be summarized here.

295 tolerated in patients with active ankylosing spondylitis who had an inadequate response or contraindi

296 -year-old woman with debilitating ankylosing spondylitis who was born to consanguineous parents was f

297 In patients of infectious spondylitis with suspected recurrence, the most common a

298 differ in their susceptibility to ankylosing spondylitis, with about 2.5 men affected for every woman

299 of the overall susceptibility to ankylosing spondylitis, with about half of the genetic contribution

300 ted arthritis progress to develop ankylosing spondylitis within 10 years after presentation.